SCHEMBL9109693

SCHEMBL9109693

Cc1ccc(CC(C(=O)O)c2cccc(Cl)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
CCKAR P32238 2/20 0.52
PPARG P37231 2/20 0.47
PPARA Q07869 2/20 0.47
ADRB3 P13945 4/20 0.46
ADRB2 P07550 2/20 0.46
ADRB1 P08588 3/20 0.46
POLB P06746 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.44
ITGB1 P05556 3/20 0.43
ITGA4 P13612 3/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
SLC2A1 P11166 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27923790 0.89 MEN1 (0.55) MEN1KMT2ACCKARPPARGPPARA
SCHEMBL9109356 0.89 MEN1 (0.55) MEN1KMT2AADRB3ADRB2ADRB1
SCHEMBL8869646 0.88 MEN1 (0.64) MEN1KMT2ACCKARPPARGPPARA
SCHEMBL9110049 0.87 MEN1 (0.53) MEN1KMT2ACCKARADRB3ADRB1
SCHEMBL9101178 0.86 MEN1 (0.52) MEN1KMT2ACCKARADRB3ADRB2
SCHEMBL15552555 0.85 MEN1 (0.60) MEN1KMT2ACCKARPPARGPPARA
SCHEMBL22394826 0.83 SMN1; SMN2 (0.56) MEN1KMT2APPARGPPARACYP2C19
SCHEMBL15553711 0.80 S1PR3 (0.46) MEN1KMT2ACCKARADRB3ADRB2
SCHEMBL22394811 0.79 MEN1 (0.56) MEN1KMT2APPARGPPARA
SCHEMBL2109907 0.79 MEN1 (0.63) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2646027-B1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN INC (US) 2014-10-15 EP disclosed
US-8697733-B2 Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2014-04-15 US disclosed
US-20130338195-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. 2013-12-19 US disclosed
US-8492410-B2 Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2013-07-23 US disclosed
US-20130150411-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-06-13 US disclosed
US-8399492-B2 Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2013-03-19 US disclosed
US-20120142736-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150411-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 MEN1 3719/4885KMT2A 4068/4885CCKAR 1157/4885
US-20130338195-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 MEN1 3719/4885KMT2A 4068/4885CCKAR 1157/4885
US-20120142736-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 MEN1 3719/4885KMT2A 4068/4885CCKAR 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.